Atabecestat在临床前阿尔茨海默病中的疗效、安全性和生物标志物结果:一项提前终止的随机2b/3期临床试验
EARLY试验评估口服β-分泌酶抑制剂atabecestat对临床前阿尔茨海默病认知衰退的作用,因肝相关不良事件提前终止。557名淀粉样蛋白阳性认知正常者随机接受5mg、25mg或安慰剂;25mg组在6个月和12个月时认知显著恶化,停药6个月后认知恶化和不良事件显示可逆。
要点
- atabecestat 25mg组在6个月和12个月时临床前阿尔茨海默认知复合评分较安慰剂显著恶化。
- 治疗中出现全身性和神经精神相关不良事件在atabecestat组更多。
- 停药6个月后认知恶化和不良事件显示可逆性。
核心结论
- atabecestat治疗与剂量相关的认知恶化相关,最早在3个月出现,并伴有神经精神治疗中出现的不良事件,停药6个月后有可逆证据。
研究设计与样本
- 从4464名筛选者中随机557名淀粉样蛋白阳性、认知正常(临床痴呆评定量表0;60-85岁)参与者,约原计划1650名的34%。
- 参与者按1:1:1随机接受atabecestat 5mg(n=189)、25mg(n=183)或安慰剂(n=185)。
主要发现
- 25mg组临床前阿尔茨海默认知复合评分在6个月时最小二乘均数差为-1.09(95%CI -1.66至-0.53;P<.001),12个月时为-1.62(95%CI -2.49至-0.76;P<.001)。
- 25mg组可重复神经心理状态评估成套测验总分在3个月时最小二乘均数为-3.70(95%CI -5.76至-1.63;P<.001)。
- 认知功能指数参与者报告在12个月时显示非显著恶化。
- atabecestat组全身性和神经精神相关治疗中出现的不良事件多于安慰剂组。
- 停药后随访认知测试和不良事件评估提供atabecestat组药物诱导的认知恶化和不良事件可逆的证据。
临床怎么用
- atabecestat因肝相关不良事件提前终止,25mg组出现剂量相关认知恶化和神经精神不良事件,停药后可逆。
局限性
- 研究提前终止,样本量约原计划的34%,可能影响统计效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Atabecestat, a nonselective oral β-secretase inhibitor, was evaluated in the EARLY trial for slowing cognitive decline in participants with preclinical Alzheimer disease. Preliminary analyses suggested dose-related cognitive worsening and neuropsychiatric adverse events (AEs). OBJECTIVE: To report efficacy, safety, and biomarker findings in the EARLY trial, both on and off atabecestat treatment, with focus on potential recovery of effects on cognition and behavior. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, phase 2b/3 study conducted from November 2015 to December 2018 after being stopped prematurely. The study was conducted at 143 centers across 14 countries. Participants were permitted to be followed off-treatment by the original protocol, collecting safety and efficacy data. From 4464 screened participants, 557 amyloid-positive, cognitively normal (Clinical Dementia Rating of 0; aged 60-85 years) participants (approximately 34% of originally planned 1650) were randomized before the trial sponsor stopped enrollment. INTERVENTIONS: Participants were randomized (1:1:1) to atabecestat, 5 mg (n = 189), 25 mg (n = 183), or placebo (n = 185). MAIN OUTCOMES AND MEASURES: Primary outcome: change from baseline in Preclinical Alzheimer Cognitive Composite score. Secondary outcomes: change from baseline in the Cognitive Function Index and the Repeatable Battery for the Assessment of Neuropsychological Status total scale score. Safety was monitored throughout the study. RESULTS: Of 557 participants, 341 were women (61.2%); mean (SD) age was 70.4 (5.56) years. In May 2018, study medication was stopped early owing to hepatic-related AEs; participants were followed up off-treatment for 6 months. Atabecestat, 25 mg, showed significant cognitive worsening vs placebo for Preclinical Alzheimer Cognitive Composite at month 6 (least-square mean difference, -1.09; 95% CI, -1.66 to -0.53; P < .001) and month 12 (least-square mean, -1.62; 95% CI, -2.49 to -0.76; P < .001), and at month 3 for Repeatable Battery for the Assessment of Neuropsychological Status (least-square mean, -3.70; 95% CI, -5.76 to -1.63; P < .001). Cognitive Function Index participant report showed nonsignificant worsening at month 12. Systemic and neuropsychiatric-related treatment-emergent AEs were greater in atabecestat groups vs placebo. After stopping treatment, follow-up cognitive testing and AE assessment provided evidence of reversibility of drug-induced cognitive worsening and AEs in atabecestat groups. CONCLUSIONS AND RELEVANCE: Atabecestat treatment was associated with dose-related cognitive worsening as early as 3 months and presence of neuropsychiatric treatment-emergent AEs, with evidence of reversibility after 6 months off treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02569398.
引用
- Sperling R, Henley D, Aisen PS, et al. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. JAMA Neurol. 2021. PMID: 33464300. doi:10.1001/jamaneurol.2020.4857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。